Logo image of NURO

NEUROMETRIX INC (NURO) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:NURO - US6412558800 - Common Stock

4.58 USD
+0.22 (+5.05%)
Last: 5/1/2025, 9:21:09 PM
4.53 USD
-0.05 (-1.09%)
After Hours: 5/1/2025, 9:21:09 PM

NURO Key Statistics, Chart & Performance

Key Statistics
Market Cap9.43M
Revenue(TTM)3.03M
Net Income(TTM)-7.81M
Shares2.06M
Float1.75M
52 Week High4.73
52 Week Low2.66
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.03
PEN/A
Fwd PEN/A
Earnings (Next)05-13
IPO2004-07-22
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
NURO short term performance overview.The bars show the price performance of NURO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10

NURO long term performance overview.The bars show the price performance of NURO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of NURO is 4.58 USD. In the past month the price increased by 3.6%. In the past year, price increased by 6.51%.

NEUROMETRIX INC / NURO Daily stock chart

NURO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to NURO. When comparing the yearly performance of all stocks, NURO is one of the better performing stocks in the market, outperforming 79.56% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NURO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NURO. NURO has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NURO Financial Highlights

Over the last trailing twelve months NURO reported a non-GAAP Earnings per Share(EPS) of -4.03. The EPS decreased by -98.82% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -50.94%
ROE -54.54%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%38.94%
Sales Q2Q%-55.77%
EPS 1Y (TTM)-98.82%
Revenue 1Y (TTM)-48.58%

NURO Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

NURO Ownership

Ownership
Inst Owners10.91%
Ins Owners14.78%
Short Float %N/A
Short RatioN/A

NURO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 24.4 211.72B
ISRG INTUITIVE SURGICAL INC 62.14 189.66B
SYK STRYKER CORP 27.62 139.12B
BSX BOSTON SCIENTIFIC CORP 29.85 130.56B
BDX BECTON DICKINSON AND CO 14.36 59.11B
IDXX IDEXX LABORATORIES INC 56.73 57.12B
EW EDWARDS LIFESCIENCES CORP 32.82 48.95B
RMD RESMED INC 26.02 37.60B
GEHC GE HEALTHCARE TECHNOLOGY 17.81 37.24B
DXCM DEXCOM INC 37.39 27.12B
PODD INSULET CORP 62.95 20.24B
ZBH ZIMMER BIOMET HOLDINGS INC 10.79 17.30B

Related stock screener links

About NURO

Company Profile

NURO logo image NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2004-07-22. The firm's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The firm has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. The company operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Company Info

NEUROMETRIX INC

1000 Winter Street

Waltham MASSACHUSETTS 01801 US

CEO: Shai N. Gozani

Employees: 13

NURO Company Website

NURO Investor Relations

Phone: 17818909989

NEUROMETRIX INC / NURO FAQ

Can you describe the business of NEUROMETRIX INC?

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2004-07-22. The firm's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The firm has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. The company operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.


Can you provide the latest stock price for NEUROMETRIX INC?

The current stock price of NURO is 4.58 USD. The price increased by 5.05% in the last trading session.


Does NURO stock pay dividends?

NURO does not pay a dividend.


What is the ChartMill technical and fundamental rating of NURO stock?

NURO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of NURO stock?

NEUROMETRIX INC (NURO) has a market capitalization of 9.43M USD. This makes NURO a Nano Cap stock.


Who owns NEUROMETRIX INC?

You can find the ownership structure of NEUROMETRIX INC (NURO) on the Ownership tab.